Serum and salivary inflammatory biomarkers in juvenile idiopathic arthritis-an explorative cross-sectional study.
Adolescents
Biomarkers
Children
Disease activity
Inflammation
Juvenile idiopathic arthritis
Saliva
Serum
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
09 Mar 2024
09 Mar 2024
Historique:
received:
15
11
2023
accepted:
21
02
2024
medline:
10
3
2024
pubmed:
10
3
2024
entrez:
9
3
2024
Statut:
epublish
Résumé
Biomarkers may be useful in monitoring disease activity in juvenile idiopathic arthritis (JIA). With new treatment options and treatment goals in JIA, there is an urgent need for more sensitive and responsive biomarkers. We aimed to investigate the patterns of 92 inflammation-related biomarkers in serum and saliva in a group of Norwegian children and adolescents with JIA and controls and in active and inactive JIA. In addition, we explored whether treatment with tumor necrosis factor inhibitors (TNFi) affected the biomarker levels. This explorative, cross-sectional study comprised a subset of children and adolescents with non-systemic JIA and matched controls from the Norwegian juvenile idiopathic arthritis study (NorJIA Study). The JIA group included individuals with clinically active or inactive JIA. Serum and unstimulated saliva were analyzed using a multiplex assay of 92 inflammation-related biomarkers. Welch's t-test and Mann-Whitney U-test were used to analyze the differences in biomarker levels between JIA and controls and between active and inactive disease. We included 42 participants with JIA and 30 controls, predominantly females, with a median age of 14 years. Of the 92 biomarkers, 87 were detected in serum, 73 in saliva, and 71 in both biofluids. A pronounced difference between serum and salivary biomarker patterns was found. Most biomarkers had higher levels in serum and lower levels in saliva in JIA versus controls, and in active versus inactive disease. In serum, TNF and S100A12 levels were notably higher in JIA and active disease. The TNF increase was less pronounced when excluding TNFi-treated individuals. In saliva, several biomarkers from the chemokine family were distinctly lower in the JIA group, and levels were even lower in active disease. In this explorative study, the serum and salivary biomarker patterns differed markedly, suggesting that saliva may not be a suitable substitute for serum when assessing systemic inflammation in JIA. Increased TNF levels in serum may not be a reliable biomarker for inflammatory activity in TNFi-treated children and adolescents with JIA. The lower levels of chemokines in saliva in JIA compared to controls and in active compared to inactive disease, warrant further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Biomarkers may be useful in monitoring disease activity in juvenile idiopathic arthritis (JIA). With new treatment options and treatment goals in JIA, there is an urgent need for more sensitive and responsive biomarkers.
OBJECTIVE
OBJECTIVE
We aimed to investigate the patterns of 92 inflammation-related biomarkers in serum and saliva in a group of Norwegian children and adolescents with JIA and controls and in active and inactive JIA. In addition, we explored whether treatment with tumor necrosis factor inhibitors (TNFi) affected the biomarker levels.
METHODS
METHODS
This explorative, cross-sectional study comprised a subset of children and adolescents with non-systemic JIA and matched controls from the Norwegian juvenile idiopathic arthritis study (NorJIA Study). The JIA group included individuals with clinically active or inactive JIA. Serum and unstimulated saliva were analyzed using a multiplex assay of 92 inflammation-related biomarkers. Welch's t-test and Mann-Whitney U-test were used to analyze the differences in biomarker levels between JIA and controls and between active and inactive disease.
RESULTS
RESULTS
We included 42 participants with JIA and 30 controls, predominantly females, with a median age of 14 years. Of the 92 biomarkers, 87 were detected in serum, 73 in saliva, and 71 in both biofluids. A pronounced difference between serum and salivary biomarker patterns was found. Most biomarkers had higher levels in serum and lower levels in saliva in JIA versus controls, and in active versus inactive disease. In serum, TNF and S100A12 levels were notably higher in JIA and active disease. The TNF increase was less pronounced when excluding TNFi-treated individuals. In saliva, several biomarkers from the chemokine family were distinctly lower in the JIA group, and levels were even lower in active disease.
CONCLUSION
CONCLUSIONS
In this explorative study, the serum and salivary biomarker patterns differed markedly, suggesting that saliva may not be a suitable substitute for serum when assessing systemic inflammation in JIA. Increased TNF levels in serum may not be a reliable biomarker for inflammatory activity in TNFi-treated children and adolescents with JIA. The lower levels of chemokines in saliva in JIA compared to controls and in active compared to inactive disease, warrant further investigation.
Identifiants
pubmed: 38461338
doi: 10.1186/s12969-024-00972-6
pii: 10.1186/s12969-024-00972-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Informations de copyright
© 2024. The Author(s).
Références
Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.
pubmed: 17336654
doi: 10.1016/S0140-6736(07)60363-8
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.
pubmed: 14760812
Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112–7.
pubmed: 24210707
doi: 10.1016/j.jbspin.2013.09.003
Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135.
pubmed: 34425842
pmcid: 8383464
doi: 10.1186/s12969-021-00629-8
de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66(5):589–98.
pubmed: 17170049
doi: 10.1136/ard.2006.061853
Qu H, Sundberg E, Aulin C, Neog M, Palmblad K, Horne AC, et al. Immunoprofiling of active and inactive systemic juvenile idiopathic arthritis reveals distinct biomarkers: a single-center study. Pediatr Rheumatol Online J. 2021;19(1):173.
pubmed: 34963488
pmcid: 8713412
doi: 10.1186/s12969-021-00660-9
Cimaz R, Maioli G, Calabrese G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2020;20(7):725–40.
pubmed: 32116038
doi: 10.1080/14712598.2020.1733524
Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–34.
pubmed: 31021516
doi: 10.1002/acr.23870
Armaroli G, Klein A, Ganser G, Ruehlmann MJ, Dressler F, Hospach A, et al. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry. Arthritis Res Ther. 2020;22(1):258.
pubmed: 33121528
pmcid: 7597050
doi: 10.1186/s13075-020-02326-5
Elfving A, Harila-Saari A, Nilsson L, Berntson L. An explorative study on proteomic analyses related to inflammation and pain in children with juvenile idiopathic arthritis. BMC Pediatr. 2023;23(1):365.
pubmed: 37454049
pmcid: 10349407
doi: 10.1186/s12887-023-04181-0
Gerss J, Tedy M, Klein A, Horneff G, Miranda-Garcia M, Kessel C, et al. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis. 2022;81(7):990–7.
pubmed: 35260388
doi: 10.1136/annrheumdis-2021-222029
Ganeva M, Fuehner S, Kessel C, Klotsche J, Niewerth M, Minden K, et al. Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline. Pediatr Rheumatol Online J. 2021;19(1):64.
pubmed: 33933108
pmcid: 8088653
doi: 10.1186/s12969-021-00553-x
Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, et al. Serum S100A8/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis: relationship to maintenance of clinically inactive disease during anti-tumor necrosis factor therapy and occurrence of disease flare after discontinuation of therapy. Arthritis Rheumatol. 2019;71(3):451–9.
pubmed: 30225949
pmcid: 6393224
doi: 10.1002/art.40727
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658–66.
pubmed: 19405003
doi: 10.1002/art.24516
Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–36.
pubmed: 21717596
doi: 10.1002/acr.20497
Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290–4.
pubmed: 15517647
Giancane G, Muratore V, Marzetti V, Quilis N, Benavente BS, Bagnasco F, et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther. 2019;21(1):168.
pubmed: 31287015
pmcid: 6615271
doi: 10.1186/s13075-019-1950-7
Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–28.
pubmed: 29643108
Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, et al. Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic juvenile idiopathic arthritis cohort. Arthritis Care Res (Hoboken). 2020;72(4):507–16.
pubmed: 30762291
doi: 10.1002/acr.23853
Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340–7.
pubmed: 22056397
doi: 10.1001/jama.2011.1671
Brown A, Hirsch R, Laor T, Hannon MJ, Levesque MC, Starz T, et al. Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging? Arthritis Care Res (Hoboken). 2012;64(12):1846–54.
pubmed: 22740386
doi: 10.1002/acr.21774
Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res. 2010;89(10):1016–23.
pubmed: 20739693
pmcid: 3144065
doi: 10.1177/0022034510380414
Collin M, Ernberg M, Christidis N, Hedenberg-Magnusson B. Salivary biomarkers in children with juvenile idiopathic arthritis and healthy age-matched controls: a prospective observational study. Sci Rep. 2022;12(1):3240.
pubmed: 35217774
pmcid: 8881454
doi: 10.1038/s41598-022-07233-0
Brik R, Rosen I, Savulescu D, Borovoi I, Gavish M, Nagler R. Salivary antioxidants and metalloproteinases in juvenile idiopathic arthritis. Mol Med. 2010;16(3–4):122–8.
pubmed: 20062821
doi: 10.2119/molmed.2009.00096
Gil EG, Åstrøm AN, Lie SA, Rygg M, Fischer J, Rosén A, et al. Dental caries in children and adolescents with juvenile idiopathic arthritis and controls: a multilevel analysis. BMC Oral Health. 2021;21(1):417.
pubmed: 34433437
pmcid: 8390188
doi: 10.1186/s12903-021-01758-y
Cetrelli L, Bletsa A, Lundestad A, Gil EG, Fischer J, Halbig J, et al. Vitamin D, oral health, and disease characteristics in juvenile idiopathic arthritis: a multicenter cross-sectional study. BMC Oral Health. 2022;22(1):333.
pubmed: 35941635
pmcid: 9361556
doi: 10.1186/s12903-022-02349-1
Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012;7(4):284–94.
pubmed: 22715120
doi: 10.1111/j.2047-6310.2012.00064.x
Júlíusson PB, Hjelmesæth J, Bjerknes R, Roelants M. New curves for body mass index among children and adolescents. Tidsskr Nor Laegeforen. 2017;137(18):1397–98.
Jonsson MV, Reksten TR, Delaleu N, Marthinussen MC. Diagnostikk av munntørrhet og bruk av saliva som diagnostisk verktøy. Norsk Tannlegeforenings Tidende. 2011;121(14):908–13.
Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192.
pubmed: 24755770
pmcid: 3995906
doi: 10.1371/journal.pone.0095192
West RM. Best practice in statistics: Use the Welch t-test when testing the difference between two groups. Ann Clin Biochem. 2021;58(4):267–9.
pubmed: 33562996
doi: 10.1177/0004563221992088
Funk RS, Chan MA, Becker ML. Cytokine biomarkers of disease activity and therapeutic response after initiating methotrexate therapy in patients with juvenile idiopathic arthritis. Pharmacotherapy. 2017;37(6):700–11.
pubmed: 28475276
doi: 10.1002/phar.1938
Spîrchez M, Samaşca G, Iancu M, Bolba C, Miu N. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab. 2012;58(3–4):253–60.
pubmed: 22582498
Walters HM, Pan N, Lehman TJ, Adams A, Kalliolias GD, Zhu YS, et al. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis. Clin Exp Immunol. 2016;184(3):308–17.
pubmed: 26934060
pmcid: 4872381
doi: 10.1111/cei.12782
Kaminiarczyk-Pyzalka D, Adamczak K, Mikos H, Klimecka I, Moczko J, Niedziela M. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA). Clin Lab. 2014;60(9):1481–90.
pubmed: 25291944
Yilmaz M, Kendirli SG, Altintas D, Bingöl G, Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol. 2001;20(1):30–5.
pubmed: 11254238
doi: 10.1007/s100670170100
Majster M, Lira-Junior R, Höög CM, Almer S, Boström EA. Salivary and serum inflammatory profiles reflect different aspects of inflammatory bowel disease activity. Inflamm Bowel Dis. 2020;26(10):1588–96.
pubmed: 32725166
pmcid: 7500518
doi: 10.1093/ibd/izaa190
Kahn R, Berthold E, Gullstrand B, Schmidt T, Kahn F, Geborek P, et al. Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis. Acta Paediatr. 2016;105(4):427–32.
pubmed: 26707699
pmcid: 5066673
doi: 10.1111/apa.13319
Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. Febs j. 2018;285(16):2944–71.
pubmed: 29637711
pmcid: 6120486
doi: 10.1111/febs.14466
Rinderknecht C, Filippi C, Ritz N, Fritschi N, Simmen U, Filippi A, et al. Associations between salivary cytokines and oral health, age, and sex in healthy children. Sci Rep. 2022;12(1):15991.
pubmed: 36163488
pmcid: 9512800
doi: 10.1038/s41598-022-20475-2
Rudney JD. Does variability in salivary protein concentrations influence oral microbial ecology and oral health? Crit Rev Oral Biol Med. 1995;6(4):343–67.
pubmed: 8664423
doi: 10.1177/10454411950060040501
Petrovsky N, McNair P, Harrison LC. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine. 1998;10(4):307–12.
pubmed: 9617577
doi: 10.1006/cyto.1997.0289
Schirmer M, Kumar V, Netea MG, Xavier RJ. The causes and consequences of variation in human cytokine production in health. Curr Opin Immunol. 2018;54:50–8.
pubmed: 29913309
doi: 10.1016/j.coi.2018.05.012
Kong F-M, Zhao L, Wang L, Chen Y, Hu J, Fu X, et al. Ensuring sample quality for blood biomarker studies in clinical trials: a multicenter international study for plasma and serum sample preparation. Translational Lung Cancer Research. 2017;6(6):625–34.
pubmed: 29218266
pmcid: 5709139
doi: 10.21037/tlcr.2017.09.13
Szabo YZ, Slavish DC. Measuring salivary markers of inflammation in health research: a review of methodological considerations and best practices. Psychoneuroendocrinology. 2021;124:105069.
pubmed: 33316694
doi: 10.1016/j.psyneuen.2020.105069
Riis JL, Out D, Dorn LD, Beal SJ, Denson LA, Pabst S, et al. Salivary cytokines in healthy adolescent girls: Intercorrelations, stability, and associations with serum cytokines, age, and pubertal stage. Dev Psychobiol. 2014;56(4):797–811.
pubmed: 23868603
doi: 10.1002/dev.21149